Oxford BioMedica PLC (OXBDF)

[marcusl2]

14:05 Advances in CAR-T Therapy for Chronic Lymphocytic Leukemia (CLL)

J. Joseph Melenhorst, PhD, Director, Product Development & Correlative Sciences, Center for Cellular Immunotherapies, University of Pennsylvania

We have shown that CD19-specific chimeric antigen receptor (CAR) T cell therapy can induce durable remission in most patients with acute but not chronic lymphocytic leukemia (ALL and CLL). We have now identified markers predictive of response and identified key mechanisms of response in CLL. Our preclinical studies have informed next-generation CAR-T based therapies for CLL. Our current trial in CLL has trumped our highest expectations in terms of response rate.

Table 2: Potential of CAR-T Therapy for Solid Tumours

Moderator: Boris Engels, PhD, Senior Investigator, Exploratory Immuno-Oncology, Novartis, Inc.